IP Library › Granted Patent US 11,344,536
Granted Patent B1
US 11,344,536 · App. 17/583,985 · Granted May 31, 2022

Methods of treating gastrointestinal stromal tumors

Inventors: Rodrigo Ruiz Soto (Waltham, MA); Oliver Rosen (Waltham, MA); Jama Pitman (Waltham, MA)
Assignee: Deciphera Pharmaceuticals, LLC
A61K31/4375A61K31/4745A61P9/12A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,344,536
App. No.
17/583,985
Granted
May 31, 2022
Kind
B1
Abstract

The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

Claims (6)

1. A method of treating a patient suffering from Grade 3 hypertension while being administered 150 mg ripretinib daily or twice daily for treatment of gastrointestinal stromal tumors, comprising:

withholding administration of ripretinib until the patient's blood pressure is controlled, and

if the patient has less than or equal to Grade 1 blood pressure, administering to the patient 150 mg daily ripretinib, or

if the patient has more than Grade 1 blood pressure, administering to the patient 100 mg daily ripretinib.

2. The method of claim 1 , wherein the method comprises withholding administration of ripretinib until the patient's blood pressure is controlled, and if the patient has less than or equal to Grade 1 blood pressure, administering to the patient 150 mg daily ripretinib.

3. The method of claim 1 , wherein the method comprises withholding administration of ripretinib until the patient's blood pressure is controlled, and if the patient has more than Grade 1 blood pressure, administering to the patient 100 mg daily ripretinib.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2023
From: SOTO, RODRIGO RUIZ; ROSEN, OLIVER; PITMAN, JAMA
To: DECIPHERA PHARMACEUTICALS, LLC
Reel/Frame 062268/0955 →
Continuity (11)
Continuation 17180218 · Feb 19, 2021
Division 17028640 · Sep 22, 2020
Continuation PCTUS2020045876 · Aug 12, 2020
Provisional Application 63023921 · May 13, 2020
Provisional Application 63023936 · May 13, 2020
Provisional Application 62968927 · Jan 31, 2020
Provisional Application 62968945 · Jan 31, 2020
Provisional Application 62936018 · Nov 15, 2019
Provisional Application 62926281 · Oct 25, 2019
Provisional Application 62904198 · Sep 23, 2019
Provisional Application 62885797 · Aug 12, 2019
Cited By (11)
US 12,213,967 US 12,213,968 US 12,226,406 US 12,295,944 US 12,318,373 US 12,318,374 US 12,319,655 US 12,509,456 US 12,577,249 US 12,616,683 US 12,708,617